Polygenic risk scores for blood pressure to assess the risk of severe bevacizumab-induced hypertension in cancer patients (Alliance)
- Citation:
- Clin Pharmacol Ther vol 112 (2) 364-371
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 11
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA232760, UG1CA233373, AHA Award Number 826128
- Corr. Author:
- Authors:
- Julia C. F. Quintanilha Amy S. Etheridge Brady J. Graynor Nicholas B. Larson Daniel J. Crona Braxton D. Mitchell Federico Innocenti
- Networks:
- LAPS-NC007
- Study
- Alliance-A152114
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401
- Phases:
- N/A, 3
- Keywords:
- bevacizumab, hypertension, polygenic risk score, blood pressure